FLOW trial shows semaglutide improves quality of life in diabetes and kidney disease patients
June 04, 2026 | 09:50
New findings from the landmark FLOW trial presented at the 63rd ERA Congress show that once-weekly semaglutide significantly improved health-related quality of life in adults with type 2 diabetes and chronic kidney disease.
Latest News
Mobile Version